A 60-Year-Old Woman with Later Relapse/Refractory Multiple Myeloma

Surbhi Sidana, MD, discusses how the treatment landscape for early to later relapsed/refractory multiple myeloma has evolved over time.

A hematologist/oncologist outlines the key unmet needs and challenges in the treatment of patients with relapsed/refractory multiple myeloma.

An expert on relapsed/refractory multiple myeloma discusses ongoing studies that may further support the utilization of CAR T-cell therapy in treatment paradigms.

Surbhi Sidana, MD, reflects on clinical trial data that inform the role of stem cell transplantation in the treatment of patients with relapsed/refractory multiple myeloma.

Focusing on a clinical scenario in which a patient receives early-line CAR T-cell therapy and relapses, Surbhi Sidana, MD, shares insights on treatment sequencing and the role of bispecific antibodies.

An expert on relapsed/refractory multiple myeloma discusses key strategies that community-based clinicians can leverage to effectively manage and support patients.

Looking to the future treatment landscape for relapsed/refractory multiple myeloma, Surbhi Sidana, MD, highlights ongoing research and discusses potential opportunities for improving care.